The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will ...

Additional evidence has prompted NICE to launch a second consultation on its decision not to recommend new Alzheimer’s ...

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

St. Charles, Missouri, resident Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now ...

While Alzheimer's has no cure, most treatments cater to the symptoms of the disease. However, a new study has shown that two ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to ...

The European Medicines Association (EMA) has upheld its decision to recommend the Alzheimer’s drug lecanemab despite concerns that any clinical benefits are small and there is a risk of brain swelling ...

In October 2024, the TGA made the decision not to register lecanemab (LEQEMBI) on the Australian Register of Therapeutic Goods (ARTG) for the ...

Eisai remains committed to ensuring eligible Australians with early Alzheimer's disease can access lecanemab and is exploring options to achieve this, including potentially seeking review by the ...

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia TOKY ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, ...